Hepatocellular Carcinoma, HCC
- Most common type
- It originates from liver cells and often develops based on chronic liver disease.
Online Inquiry
Your Information Is Secure. We Respect Your Privacy And Never Spam.
Liver cancer is the leading cause of cancer-related death worldwide. It often stems from chronic liver disease, such as hepatitis B/C, cirrhosis, or non-alcoholic fatty liver disease. Developing effective treatments remains challenging for multiple complex reasons. Current therapies include surgery, chemotherapy, targeted therapy, immunotherapy, gene therapy, and combination therapy.
Hepatocellular Carcinoma, HCC
Intrahepatic Cholangiocarcinoma, ICC
Combined Hepatocellular-Cholangiocarcinoma, cHCC-CCA
Hepatoblastoma
Fibrolamellar Carcinoma, FLC
Metastatic Liver Cancer
Developing effective therapies for liver cancer presents several significant challenges due to the complex nature of the disease and the unique environment of the liver.
With extensive experience in preclinical research, Alfa Cytology provides cutting-edge services to accelerate liver cancer therapy development. By leveraging advanced technologies and a deep understanding of liver cancer biology, we support the development of innovative, safe, and effective therapies. Partner with us to transform liver cancer therapy.
Significant progress has been made in liver cancer therapy, with some innovative therapies emerging. As a leader in novel therapy development for liver cancer, Alfa Cytology has extensive experience in cutting-edge treatment option development and pre-clinical services. Our areas of expertise cover but are not limited to the following.
Targeted Therapy
Immunotherapy
Gene Therapy
Radiation Therapy
Cell Therapy
Epigenetic Therapy
Metabolic Therapy
Combination Therapy
During the development of liver cancer therapies, multiple experiments are needed to evaluate the efficacy, safety, and mechanism of action of drugs or therapies. Alfa Cytology's experimental technology platform includes a one-stop evaluation program that includes in vitro evaluation, in vivo assessment, and mechanistic research
Explore More
Drug Screening and Optimization is a critical process in drug discovery and development to identify and refine potential drug candidates for further development. It involves a series of scientific and technical steps to select the most promising compounds and optimize their properties for efficacy, safety, and pharmacokinetics.
Explore More
The biological technology platform developed by Alfa Cytology is a comprehensive experimental and technology platform for liver cancer therapy development, designed to support the full process of research, from target validation to drug candidate screening. It covers a variety of experimental equipment, from molecules, and cells to animal models. Through this platform, our researchers can systematically validate targets, screen drugs, and evaluate efficacy and safety, thereby accelerating the development of new drugs for liver cancer.
Equipment
Experiment
Test/Assay
Project Consulting and Demand Analysis
Program Design and Protocol Formulation
Project Start-up and Resource Allocation
Experiment Execution and Data Collection
Data Analysis and Verification
Report Writing and Delivery
Project Summary and Follow-up Support
Quality Assurance and Compliance
Intellectual Property and Confidentiality
What preclinical development services do you offer for liver cancer therapies?
Alfa Cytology provides comprehensive preclinical development services for liver cancer therapies, including target validation, drug screening, pharmacodynamic evaluation, pharmacokinetic (PK) studies, toxicological (Tox) evaluation, biomarker development, and IND filing support.
Do you support customization?
Yes, Alfa Cytology can provide customized service solutions according to the specific needs of our customers, covering the full process from early-stage research to pre-clinical development or modular services.
What technology platforms do you use for liver cancer therapy development?
Alfa Cytology has advanced molecular biology, cell biology, and animal experimental platforms, including CRISPR/Cas9 gene editing, 3D cell culture, high throughput screening (HTS), flow cytometry, small animal imaging (e.g. IVIS, MRI), etc.
What experimental models of liver cancer do you use?
Alfa Cytology uses a variety of liver cancer models, including liver cancer cell lines, patient-derived xenotransplantation models (PDX), genetically engineered mouse models (GEMM), and organoid models.